Pharmaceutical composition containing polypeptide fragments...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S021200, C435S220000

Reexamination Certificate

active

08076297

ABSTRACT:
The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.

REFERENCES:
patent: 2004/0185566 (2004-09-01), Salamone
patent: 0226800 (1987-07-01), None
patent: 2519021 (1983-07-01), None
patent: WO 99/15690 (1999-04-01), None

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Pharmaceutical composition containing polypeptide fragments... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition containing polypeptide fragments..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition containing polypeptide fragments... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4258186

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.